Prostate-specific membrane antigen-based imaging

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 2, 2013, Pages 144-154

  Osborne, Joseph R ^a   Akhtar, Naveed H ^a   Vallabhajosula, Shankar ^a   Anand, Alok ^a   Deh, Kofi ^a   Tagawa, Scott T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Molecular imaging; Monoclonal antibody; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen; Single photon emission computed tomography

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CAPROMAB PENDETIDE IN 111; IOFOLASTAT I 123; MIP 1095; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BONE METASTASIS; CANCER RECURRENCE; DIAGNOSTIC IMAGING; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 84875271267     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.016     Document Type: Review

References (57)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Turkbey B., Pinto P.A., Choyke P.L. Imaging techniques for prostate cancer: Implications for focal therapy. Nat Rev Urol 2009, 6:191-203.
3. Segall G., Delbke D., Stabin M.G., et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010, 51:1813-1820.
4. Ghosh A., Heston W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004, 91:528-539.
5. Ross J.S., Gray K.E., Webb I.J., et al. Antibody-based therapeutics: Focus on prostate cancer. Cancer Metastasis Rev 2005, 24:521-537.
6. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987, 7:927-935.
7. Israeli R.S., Powell C.T., Fair W.R., et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993, 53:227-230.
8. Israeli R.S., Powell C.T., Corr J.G., et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994, 54:1807-1811.
9. Troyer J.K., Beckett M.L., Wright G.L. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995, 62:552-558.
10. Sokoloff R.L., Norton K.C., Gasior C.L., et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000, 43:150-157.
11. Bostwick D.G., Pacelli A., Blute M., et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998, 82:2256-2261.
12. Kusumi T., Koie T., Tanaka M., et al. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int 2008, 58:687-694.
13. Mannweiler S., Amersdorfer P., Trajanoski S., et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009, 15:167-172.
14. Ananias H.J., van den Heuvel M.C., Helfrich W., et al. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009, 69:1101-1108.
15. Wright G.L., Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995, 1:18-28.
16. Wright G.L., Grob B.M., Haley C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48:326-334.
17. Sweat S.D., Pacelli A., Murphy G.P., et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998, 52:637-640.
18. Troyer J.K., Beckett M.L., Wright G.L. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995, 62:552-558.
19. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81-85.
20. Laidler P., Dulińska J., Lekka M., et al. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005, 435:1-14.
21. Rajasekaran S.A., Anilkumar G., Oshima E., et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003, 14:4835-4845.
22. Elsasser-Beile U., Wolf P., Gierschner D., et al. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006, 66:1359-1370.
23. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991, 18:229-241.
24. Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008, 49:2031-2041.
25. Troyer J.K., Beckett M.L., Wright G.L. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997, 30:232-242.
26. Tagawa S.T., Beltran H., Vallabhajosula S., et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010, 116:1075-1083.
27. Smith-Jones P.M., Vallabhajosula S., Navarro V., et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003, 44:610-617.
28. Alt K., Wiehr S., Ehrlichmann W., et al. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010, 70:1413-1421.
29. Wolf P., Freudenberg N., Buhler P., et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010, 70:562-569.
30. Elsasser-Beile U., Reischl G., Wiehr S., et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009, 50:606-611.
31. Regino C.A., Wong K.J., Milenic D.E., et al. Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2009, 2:9-17.
32. Maresca K.P., Hillier S.M., Femia F.J., et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem 2009, 52:347-357.
33. Foss C.A., Mease R.C., Fan H., et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005, 11:4022-4028.
34. Mease R.C., Dusich C.L., Foss C.A., et al. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-l-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin Cancer Res 2008, 14:3036-3043.
35. Chen Y., Dhara S., Banerjee S.R., et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009, 390:624-629.
36. Hillier S.M., Maresca K.P., Femia F.J., et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009, 69:6932-6940.
37. Lapi S.E., Wahnishe H., Pham D., et al. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 2009, 50:2042-2048.
38. Sodee D.B., Conant R., Chalfant M., et al. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint) in the detection of recurrent prostate cancer. Clin Nucl Med 1996, 21:759-767.
39. Deb N., Goris M., Trisler K., et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996, 2:1289-1297.
40. Manyak M.J., Hinkle G.H., Olsen J.O., et al. Immunoscintigraphy with indium-111-capromab penditide: Evaluation before definitive therapy in patients with prostate cancer. Urology 1999, 54:1058-1063.
41. Kahn D., Williams R.D., Manyak M.J., et al. 111Indium-capromab penditide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998, 159:2041-2046.
42. Levesque P.E., Nieh P.T., Zinman L.N., et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998, 51:978-984.
43. Wilkinson S., Chodak G. The role of 111indium-capromab penditide imaging for assessing biochemical failure after radical prostatectomy. J Urol 2004, 172:133-136.
44. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-111-capromab penditide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003, 21:1715-1721.
45. DeWyngaert J.K., Noz M.E., Ellerin B., et al. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 2004, 60:654-662.
46. Schettino C.J., Kramer E.L., Noz M.E., et al. Impact of fusion of indium-111 capromab penditide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol 2004, 183:519-524.
47. Sodee D.B., Sodee A.E., Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007, 37:17-28.
48. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathologic correlation. Int J Radiat Oncol Biol Phys 2001, 49:1281-1286.
49. Bander N.H., Milowsky M.I., Nanus D.M., et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23:4591-4601.
50. Milowsky M.I., Nanus D.M., Kostakoglu L., et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004, 22:2522-2531.
51. Bander N.H. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006, 3:216-225.
52. Akhtar N.H., Nanus D.M., Osborne J.R., et al. Antiprostate-specific membrane antigen (PSMA)-based radioimmunotherapy: A combined analysis of radiolabeled-J591 studies. J Clin Oncol 2011, 29(Suppl 7). Abstract 136.
53. Holland J.P., Divilov V., Bander N.H., et al. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010, 51:1293-1300.
54. Nakajima T., Mitsunaga M., Bander N.H., et al. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem 2011, 22:1700-1705.
55. Evans M.J., Smith-Jones P.M., Wongvipat J., et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011, 108:9578-9582.
56. 123I-MIP1095. J Nucl Med 2009, 50:522.
57. Osborne J.R., Akhtar N.H., Vallabhajosula S., et al. Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC). J Clin Oncol 2012, 30(Suppl 5). Abstract 173.